Does gender influence clinical expression and disease outcomes in COVID-19? A systematic review and meta-analysis.
COVID-19
Gender
Meta-Analysis
Systematic review
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
26
05
2020
revised:
15
07
2020
accepted:
19
07
2020
pubmed:
18
8
2020
medline:
29
10
2020
entrez:
18
8
2020
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) was characterized at the end of 2019, and soon spread around the world, generating a pandemic. It has been suggested that men are more severely affected by the viral disease (COVID-19) than women. The aim of this systematic literature review (SRL) and meta-analysis was to analyse the influence of gender on COVID-19 mortality, severity, and disease outcomes. A SRL was performed in PubMed and Embase, searching terms corresponding to the 'PEO' format: population = adult patients affected with COVID-19; exposure = gender; outcome = any available clinical outcomes by gender, including mortality and disease severity. The search covered the period from January 1 to April 30, 2020. Exclusion criteria were: case reports/series, reviews, commentaries, languages other than English. Full-text, original articles were included. Data on study type, country, and patients' characteristics were extracted. Study quality was evaluated using the Newcastle-Ottawa scale (NOS). From a total of 950 hits generated by the database search, 85 articles fulfilling the inclusion criteria were selected. A random-effects meta-analysis was performed to compare mortality, recovery rates, and disease severity in men compared with women. The male to female ratio for cases was 1:0.9. A significant association was found between male sex and mortality (OR = 1.81; 95% CI 1.25-2.62), as well as a lower chance of recovery in men (OR = 0.72; 95% CI 0.55-0.95). Male patients were more likely to present with a severe form of COVID-19 (OR = 1.46; 95% CI 1.10-1.94). Males are slightly more susceptible to SARS-CoV2 infection, present with a more severe disease, and have a worse prognosis. Further studies are warranted to unravel the biological mechanisms underlying these observations.
Sections du résumé
BACKGROUND
BACKGROUND
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) was characterized at the end of 2019, and soon spread around the world, generating a pandemic. It has been suggested that men are more severely affected by the viral disease (COVID-19) than women.
OBJECTIVE
OBJECTIVE
The aim of this systematic literature review (SRL) and meta-analysis was to analyse the influence of gender on COVID-19 mortality, severity, and disease outcomes. A SRL was performed in PubMed and Embase, searching terms corresponding to the 'PEO' format: population = adult patients affected with COVID-19; exposure = gender; outcome = any available clinical outcomes by gender, including mortality and disease severity. The search covered the period from January 1 to April 30, 2020. Exclusion criteria were: case reports/series, reviews, commentaries, languages other than English. Full-text, original articles were included. Data on study type, country, and patients' characteristics were extracted. Study quality was evaluated using the Newcastle-Ottawa scale (NOS). From a total of 950 hits generated by the database search, 85 articles fulfilling the inclusion criteria were selected.
RESULTS
RESULTS
A random-effects meta-analysis was performed to compare mortality, recovery rates, and disease severity in men compared with women. The male to female ratio for cases was 1:0.9. A significant association was found between male sex and mortality (OR = 1.81; 95% CI 1.25-2.62), as well as a lower chance of recovery in men (OR = 0.72; 95% CI 0.55-0.95). Male patients were more likely to present with a severe form of COVID-19 (OR = 1.46; 95% CI 1.10-1.94).
CONCLUSIONS
CONCLUSIONS
Males are slightly more susceptible to SARS-CoV2 infection, present with a more severe disease, and have a worse prognosis. Further studies are warranted to unravel the biological mechanisms underlying these observations.
Identifiants
pubmed: 32800858
pii: S1201-9712(20)30607-X
doi: 10.1016/j.ijid.2020.07.076
pmc: PMC7422797
pii:
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
496-504Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Clin Microbiol Infect. 2020 Jun;26(6):767-772
pubmed: 32304745
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Hum Resour Health. 2019 Jun 24;17(1):46
pubmed: 31234883
J Med Virol. 2020 Sep;92(9):1603-1608
pubmed: 32270521
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Acta Paediatr. 2015 Dec;104(467):38-53
pubmed: 26192405
Clin Infect Dis. 2020 Jul 28;71(15):799-806
pubmed: 32271376
AJR Am J Roentgenol. 2020 May;214(5):1072-1077
pubmed: 32125873
Clin Gastroenterol Hepatol. 2020 Jun;18(7):1561-1566
pubmed: 32283325
Respir Res. 2020 Mar 26;21(1):74
pubmed: 32216803
J Biol Regul Homeost Agents. 2020 Apr 07;34(2):339-343
pubmed: 32253888
BMJ. 2020 Apr 21;369:m1443
pubmed: 32317267
Crit Care. 2020 Mar 18;24(1):108
pubmed: 32188484
Z Gesundh Wiss. 2020 Apr 21;:1-4
pubmed: 32318325
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
J Infect. 2020 Jul;81(1):e6-e12
pubmed: 32283162
JAMA. 1992 Nov 4;268(17):2420-5
pubmed: 1404801
J Clin Med. 2020 Mar 30;9(4):
pubmed: 32235486
J Pharm Pharm Sci. 2020;23(1):75-85
pubmed: 32324533
Cells. 2020 Apr 09;9(4):
pubmed: 32283711
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Allergy Clin Immunol. 2020 Jul;146(1):110-118
pubmed: 32294485
J Immunol. 2017 May 15;198(10):4046-4053
pubmed: 28373583
J Med Virol. 2020 Jul;92(7):807-813
pubmed: 32222986
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Lancet. 2020 Mar 14;395(10227):846-848
pubmed: 32151325
J Clin Virol. 2020 Jun;127:104364
pubmed: 32311650
Respir Res. 2020 Apr 15;21(1):83
pubmed: 32293449
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):477-481
pubmed: 32298247
Lancet. 2020 Mar 7;395(10226):809-815
pubmed: 32151335
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67
pubmed: 31573350
Eur Rev Med Pharmacol Sci. 2020 Mar;24(6):3404-3410
pubmed: 32271459
PLoS Pathog. 2020 Apr 28;16(4):e1008520
pubmed: 32343745
Clin Infect Dis. 2020 Jul 28;71(15):748-755
pubmed: 32239127
PLoS One. 2020 Mar 19;15(3):e0230548
pubmed: 32191764
J Infect. 2020 May;80(5):e1-e6
pubmed: 32171869
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Turk J Med Sci. 2020 Apr 17;50(SI-1):620-632
pubmed: 32299202
J Infect. 2020 Apr;80(4):401-406
pubmed: 32112886
Ann Am Thorac Soc. 2020 Jul;17(7):839-846
pubmed: 32255382
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
JAMA. 2020 May 19;323(19):1915-1923
pubmed: 32275295
J Med Virol. 2020 Jul;92(7):797-806
pubmed: 32198776
J Clin Epidemiol. 2009 Oct;62(10):1006-12
pubmed: 19631508
Eur J Radiol. 2020 May;126:108941
pubmed: 32193037
Eur Respir J. 2020 May 7;55(5):
pubmed: 32269088
J Korean Med Sci. 2020 Mar 16;35(10):e112
pubmed: 32174069
Int J Infect Dis. 2020 Jun;95:421-428
pubmed: 32289565